title: Development of prophylactic vaccines against HIV-1.
abstract: The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.
authors.affiliation: The Sir William Dunn School of Pathology, The University of Oxford, South Parks Road, Oxford OX1 3RE, UK.
authors.forename: Torben
authors.initials: T
authors.lastname: Schiffner
authors.forename: Quentin J
authors.initials: QJ
authors.lastname: Sattentau
authors.forename: Lucy
authors.initials: L
authors.lastname: Dorrell
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D057134:Antibodies, Neutralizing / Q000097:blood; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000639:trends; D015483:HIV Antibodies / Q000097:blood; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies